JACC. Cardiovascular interventions
-
JACC Cardiovasc Interv · Mar 2016
Multicenter Study Comparative Study1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. ⋯ In a contemporary large cohort of patients undergoing percutaneous coronary intervention with ABSORB BRS, the combined rate of ischemic events at 1 year was low and nonsignificantly different compared with matched patients treated with XIENCE EES.
-
JACC Cardiovasc Interv · Mar 2016
Multicenter StudyTranscarotid Transcatheter Aortic Valve Replacement: Feasibility and Safety.
The purpose of this study was to assess the feasibility and safety of transcarotid transcatheter aortic valve replacement (TAVR). ⋯ Transcarotid vascular access for TAVR is feasible and is associated with encouraging short- and medium-term clinical outcomes. Prospective studies are required to ascertain if transcarotid TAVR yields equivalent results to other nonfemoral vascular access routes.